You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 9, 2024

CLINICAL TRIALS PROFILE FOR ENASIDENIB MESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ENASIDENIB MESYLATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03683433 ↗ Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Unknown status National Cancer Institute (NCI) Phase 2 2018-09-18 This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03683433 ↗ Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Unknown status M.D. Anderson Cancer Center Phase 2 2018-09-18 This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03728335 ↗ Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant Recruiting National Cancer Institute (NCI) Phase 1 2019-07-11 This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03728335 ↗ Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant Recruiting City of Hope Medical Center Phase 1 2019-07-11 This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT03825796 ↗ CPX-351 Plus Enasidenib for Relapsed AML Suspended Jazz Pharmaceuticals Phase 2 2019-04-12 This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone.
NCT03825796 ↗ CPX-351 Plus Enasidenib for Relapsed AML Suspended National Cancer Institute (NCI) Phase 2 2019-04-12 This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ENASIDENIB MESYLATE

Condition Name

Condition Name for ENASIDENIB MESYLATE
Intervention Trials
Recurrent Acute Myeloid Leukemia 5
IDH2 Gene Mutation 3
Refractory Acute Myeloid Leukemia 3
Acute Biphenotypic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ENASIDENIB MESYLATE
Intervention Trials
Leukemia, Myeloid, Acute 6
Leukemia, Myeloid 6
Leukemia 6
Leukemia, Biphenotypic, Acute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ENASIDENIB MESYLATE

Trials by Country

Trials by Country for ENASIDENIB MESYLATE
Location Trials
United States 22
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ENASIDENIB MESYLATE
Location Trials
California 4
Florida 2
Texas 2
Virginia 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ENASIDENIB MESYLATE

Clinical Trial Phase

Clinical Trial Phase for ENASIDENIB MESYLATE
Clinical Trial Phase Trials
Phase 2 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ENASIDENIB MESYLATE
Clinical Trial Phase Trials
Recruiting 2
Not yet recruiting 2
Suspended 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ENASIDENIB MESYLATE

Sponsor Name

Sponsor Name for ENASIDENIB MESYLATE
Sponsor Trials
National Cancer Institute (NCI) 6
City of Hope Medical Center 3
Children's Oncology Group 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ENASIDENIB MESYLATE
Sponsor Trials
NIH 6
Other 6
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.